<DOC>
	<DOCNO>NCT01472887</DOCNO>
	<brief_summary>Primary Objective : Participants achieve Objective Response Rate Secondary Objective : - Progression Free Survival - Overall Survival - Response Duration - Safety</brief_summary>
	<brief_title>SAR3419 Single Agent Relapsed-Refractory Diffuse Large B-Cell Lymphoma ( DLBCL ) Patients</brief_title>
	<detailed_description>The screening period = 4 week prior SAR3419 administration The treatment period = day first administration SAR3419 End-Of-Treatment visit . All patient receive SAR3419 evidence disease progression , unacceptable toxicity reason therapy discontinuation - After therapy discontinuation patient enter safety follow-up period 42 day start day administration last dose SAR3419 end End Of Treatment visit . All patient , regardless whether progress , follow death end study evaluate survival least 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Inclusion criterion : Histological diagnosis Diffuse Large B Cell Lymphoma ( de novo transform ) express CD19 immunohistochemistry flow cytometry analysis ( &gt; 30 % positivity ) , base recent ( less 6 month ) new biopsy . At least 1 prior specific therapeutic regimen , one include rituximab ( patient previously eligible transplantation : salvage treatment follow intensification Autologous Stem Cell Transplant ( ASCT ) consider one regimen ) . Relapsed disease standard 1st line therapy aggressive lymphoma eligible high dose chemotherapy stem cell support . Relapsed refractory disease two line therapy one could include Autologous Stem Cell Transplant ( ASCT ) . Relapsed disease define progression disease free interval least 6 month completion last therapy . Refractory define progression disease prior therapy within 6 month completion . Available paraffinembedded tissue collect longer 6 month prior first administration SAR3419 . Cryopreserved tissue use . If archival material available , Fine Needle Aspiration ( FNA ) must obtain . Exclusion criterion : Primary refractory patient Patients primary mediastinal DLBCL The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>